CJC-1295 NO DAC 5mg
Short-acting synthetic GHRH analog engineered to stimulate physiological, pulsatile growth hormone secretion in laboratory models.
Mechanism
Selectively binds pituitary GHRH receptors on somatotroph cells to trigger rapid, pulsatile secretion of endogenous growth hormone without continuous axis suppression.
Dosing
Standard investigational regimens begin at 100 mcg administered once daily, frequently evaluated prior to natural nocturnal surges.
Reconstitution
Reconstituting the 5 mg vial with 3.0 mL of bacteriostatic water yields an approximate working concentration of 1.67 mg/mL (16.7 mcg per U-100 unit).
Storage
Store the unmixed lyophilized powder refrigerated between 2 and 8 °C, and consume reconstituted liquid within 7 to 14 days under refrigeration or freeze aliquots below -20 °C.
Mix & measure CJC-1295 NO DAC 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure CJC-1295 NO DAC 5mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 50.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.1 mg) once daily | 6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg (0.15 mg) once daily | 9 units (0.09 mL) |
| Weeks 5–6 | 200 mcg (0.2 mg) once daily | 12 units (0.12 mL) |
| Weeks 7–10 | 250–300 mcg (0.25–0.3 mg) once daily | 15–18 units (0.15–0.18 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- 2
Release it slowly down the vial's inner wall to limit foaming.
- 3
Swirl or roll gently until fully dissolved — don't shake.
- 4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Supplies Needed
Peptide Vial
Provides 5 mg of lyophilized CJC-1295 (No DAC) peptide material for experimental study.
Insulin Syringes (U-100)
Used for precise measurement and subcutaneous delivery of low-volume research dosages.
Bacteriostatic Water
Supplies the sterile, preserved diluent (3.0 mL per vial) necessary for reconstitution.
Alcohol Swabs
Utilized to sanitize the vial rubber stopper and test site prior to every manipulation.
Why researchers study it
GH & IGF-1 support
Fat metabolism / lipolysis
Tissue repair / recovery
Sleep & slow-wave sleep
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
CJC-1295 without Drug Affinity Complex (DAC), commonly identified as Modified GRF 1-29, represents a truncated synthetic counterpart to endogenous growth hormone-releasing hormone. The sequence contains specific amino acid substitutions that grant improved resistance to enzymatic degradation relative to native GHRH, while omitting the reactive moiety that facilitates binding to serum albumin. Because of this structural profile, the compound exhibits an approximate half-life of thirty minutes. In laboratory models, this accelerated clearance produces discrete, transient peaks in somatotroph activity rather than sustained elevations, mirroring normal physiological pulsatility. Investigations often utilize this molecule to evaluate controlled endocrine pulses, often pairing it with complementary ghrelin mimetics to observe downstream effects on circulating IGF-1 concentrations. All data presented herein are derived from experimental literature for benchwork and educational documentation only. The substance is not approved for therapeutic administration, human consumption, or diagnostic procedures.
References
- 1.Teichman SL et al., J Clin Endocrinol Metab, 2006 — Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting albumin-bound GHRH analog, in healthy adults
- 2.Ionescu M, Frohman LA, J Clin Endocrinol Metab, 2006 — Pulsatile GH secretion persists during continuous CJC-1295 stimulation, but the net effect is a sustained, non-pulsatile rise in GH and IGF-1
- 3.Alba M et al., Am J Physiol Endocrinol Metab, 2006 — Once-daily CJC-1295 (a GHRH analog) normalizes growth in a GHRH-knockout mouse model — mechanistic GHRH-receptor activation
- 4.Brinkman JE et al., StatPearls (NCBI Bookshelf), 2023 — Physiology, Growth Hormone — GH/IGF-1 axis, pulsatile secretion, and downstream signalling
- 5.Ayuk J, Sheppard MC, Postgrad Med J, 2006 — Growth hormone and its disorders — physiology and risks of GH/IGF-1 excess
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allThymosin Beta-4 10mg
Endogenous 43-amino-acid peptide evaluated in preclinical models for actin regulation, dermal healing, and cardioprotective signaling.
View ProtocolMatrixyl 3000 3-10%
Topical matrikine peptide complex evaluated in dermatological research for skin firming, extracellular matrix synthesis, and photoprotection.
View ProtocolFollistatin-344 1mg
Recombinant glycoprotein studied for myostatin inhibition, ActRIIB pathway modulation, and muscle hypertrophy in preclinical models.
View Protocol